Alejandro Iglesias, MD
Clinical Genetics (M.D.) · New York, NYNPI 1629050851
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,300 of the $3,401 with a category attached, or 67.6%. Amgen accounts for 91.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $3,150 and has fallen 95.6% since, to $139 in 2025.
Across 22 payments — averaging $154.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Ultragenyx Pharmaceutical Inc.$90
- Takeda Pharmaceuticals U.S.A., Inc.$49
- Chiesi USA, Inc.$29
- AstraZeneca$28
- Duchesnay USA Incorporated$22
- plus $68 from 4 others
What the payments were for
- Speaking & faculty fees$2,30068%
- Travel & lodging$65019%
- Food & beverage$34110%
- Education$1113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $3,115 |
| Ultragenyx Pharmaceutical Inc. | 3 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Chiesi USA, Inc. | 1 | $29 |
| AstraZeneca | 1 | $28 |
| Duchesnay USA Incorporated | 1 | $22 |
| Travere Therapeutics, Inc. | 5 | $21 |
| AbbVie | 1 | $18 |
| Sanofi | 1 | $15 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAVICTI$2,950
How this compares
$3,401 in reported general payments places this provider in the 65th percentile of 49 clinical genetics (m.d.) providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diphenhydramine Hcl | 17 | $107 |
| Ondansetron HclOndansetron Hcl/Pf | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in New York
- Robert DesnickNew York$207K
- Manisha BalwaniNew York$188K
- Jaya GaneshNew York$65K
- George DiazNew York$44K
- Christopher CunniffNew York$25K
- David BeckNew York$21K
- Kimihiko OishiNew York$15K
- Mary LopiccoloNew York$13K
- Noura Abul HusnNew York$6K
- Ronald WapnerNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.